European cystic fibrosis bone mineralisation guidelines
It uses trastuzumab as its targeting component, but the finished product is a categorically different molecule with a different mechanism of cytotoxic action, a different safety profile, and a different set of composition-of-matter patents covering the linker chemistry, the payload structure, and the conjugation method
Providers should weigh discontinuation decisions carefully in these populations and discuss restart plans proactively if stopping is unavoidable
In addition to the FDAs scrutiny of outsourcing facilities and compounders in the GLP-1 space, the FDA has expressed concerns over the use of unapproved GLP-1 drugs for weight loss, 2 including dosing concerns with compounded semaglutide and tirzepatide products, salt forms that should not be used to compound semaglutide, use of retatrutide in compounding, and adverse events related to compounded versions of semaglutide and tirzepatide, among others